OraSure Technologies Inc
orasure.comOraSure Technologies (NASDAQ: OSUR) is a diagnostics and sample collection company that develops, manufactures, and sells rapid point-of-care tests and biological sample collection devices. Revenue comes from transactional product sales across two broad categories: diagnostic tests sold to public health agencies, hospitals, clinics, and distributors, and sample collection and management products sold to research organizations and commercial laboratories. Products include the OraQuick ADVANCE HIV-1/2 antibody test, the OraQuick HCV test, the Syphilis Health Check, the InteliSwab COVID-19 Rapid Test, and sample collection devices such as the OMNIgene GUT for microbiome research and the Colli-Pee urine collection device. The company manufactures InteliSwab at its Bethlehem, Pennsylvania facilities and acquired BioMedomics in 2025 for $3.6 million. OraSure carries an accumulated deficit as of December 31, 2025 and reported net losses in both FY2024 and FY2025, while repurchasing $15.0 million of common stock under its share repurchase plan during FY2025.
Products & Services
OraQuick ADVANCE HIV-1/2 antibody test, OraQuick HCV test, Syphilis Health Check, InteliSwab COVID-19 Rapid Test, OMNIgene GUT microbiome collection device, Colli-Pee volumetric first-void urine collection device.
Revenue Model
Transactional product sales of rapid diagnostic tests and biological sample collection devices, sold directly to public health customers and through distributors domestically and internationally.
Customers & Markets
Public health agencies, state and county governments, family planning clinics, colleges and universities, correctional facilities, military, hospitals, physician offices, retail clinics, AIDS service organizations, community-based organizations, and microbiome research organizations.
Geographic Exposure
Primary manufacturing in Bethlehem, Pennsylvania. International distribution through third-party distributors in select foreign countries. Global microbiome research market engagement noted in the FY2025 10-K.
Financial Snapshot
Loading...
